PMID- 14632666
OWN - NLM
STAT- MEDLINE
DCOM- 20031215
LR  - 20190513
IS  - 0019-2805 (Print)
IS  - 1365-2567 (Electronic)
IS  - 0019-2805 (Linking)
VI  - 110
IP  - 3
DP  - 2003 Nov
TI  - Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 
      5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom 
      allergy.
PG  - 376-85
AB  - Up to 5% of the population suffer from systemic, 19% from local allergic 
      hypersensitivity reactions to stinging insects. Even though specific 
      immunotherapy is very effective in treating allergy to insect venom, new concepts 
      of treatment strategies with only the disease eliciting allergen in recombinant 
      form, along with antigen application via a less invasive route might be suggested 
      for enhanced treatment efficacy and compliance. In the present study we aimed (i) 
      to establish a mouse model of wasp venom allergy, mimicking the natural mode of 
      sensitization, and (ii) to develop a prophylactic treatment strategy based on 
      mucosal tolerance induction, using one major wasp venom allergen in recombinant 
      form, i.e. recombinant (r)Ves v 5. Immunization with wasp venom--with or without 
      the use of the adjuvant aluminium hydroxide--led to comparable T helper 2-like 
      immune responses in vivo and in vitro. Intranasal administration of rVes v 5 
      prior to sensitization with wasp venom resulted in a significant reduction of 
      wasp venom-specific antibody levels (immunoglobulin E (IgE)/IgG2a), type I 
      hypersensitivity reactions in vivo and cytokine production in vitro. Pretreatment 
      with the whole venom was less effective and caused toxic side reactions in higher 
      concentrations, suggesting a favourable use of the recombinant venom allergen for 
      mucosal application. Increased mRNA levels of transforming growth factor-beta and 
      interleukin-10, along with adoptive cell transfer experiments indicated that the 
      immunosuppression after intranasal rVes v 5-application has been mediated by 
      regulatory mechanisms. This is further supported by the fact that the 
      immunosuppression to rVes v 5 was associated with a bystander suppression to the 
      unrelated aero-allergen Bet v 1. In conclusion, we demonstrated that the 
      intranasal application of recombinant Ves v 5 prevented subsequent allergic 
      sensitization to all components of the whole wasp venom. As allergy to insect 
      venom develops in dependence of the frequency of insect stings, a prophylactic 
      treatment based on mucosal tolerance induction with recombinant allergens might 
      be of interest for people at high risk to frequent exposure to the stinging 
      insects.
FAU - Winkler, Birgit
AU  - Winkler B
AD  - Department of Pathophysiology, University of Vienna, Austria.
FAU - Bolwig, Caroline
AU  - Bolwig C
FAU - Seppala, Ulla
AU  - Seppala U
FAU - Spangfort, Michael D
AU  - Spangfort MD
FAU - Ebner, Christof
AU  - Ebner C
FAU - Wiedermann, Ursula
AU  - Wiedermann U
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Immunology
JT  - Immunology
JID - 0374672
RN  - 0 (Allergens)
RN  - 0 (Cytokines)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Ves v 5 allergen)
RN  - 0 (Wasp Venoms)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens/*therapeutic use
MH  - Animals
MH  - Cells, Cultured
MH  - Cytokines/biosynthesis
MH  - Desensitization, Immunologic/*methods
MH  - Disease Models, Animal
MH  - Female
MH  - Hypersensitivity/immunology/*prevention & control
MH  - Immunity, Mucosal
MH  - Immunoglobulin E/biosynthesis
MH  - Immunoglobulin G/biosynthesis
MH  - Insect Bites and Stings/*complications
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Recombinant Proteins/therapeutic use
MH  - Skin Tests
MH  - Spleen/immunology
MH  - Wasp Venoms/*immunology
PMC - PMC1783061
EDAT- 2003/11/25 05:00
MHDA- 2003/12/16 05:00
PMCR- 2004/11/01
CRDT- 2003/11/25 05:00
PHST- 2003/11/25 05:00 [pubmed]
PHST- 2003/12/16 05:00 [medline]
PHST- 2003/11/25 05:00 [entrez]
PHST- 2004/11/01 00:00 [pmc-release]
AID - 1751 [pii]
AID - 10.1046/j.1365-2567.2003.01751.x [doi]
PST - ppublish
SO  - Immunology. 2003 Nov;110(3):376-85. doi: 10.1046/j.1365-2567.2003.01751.x.